Health insurer Elevance has filed a lawsuit against the federal government over $115 million it claims is tied to improperly calculated Medicare Advantage star ratings, according to reporting by STAT News.
The Core of the Dispute
At the heart of the case is Elevance's allegation that the Centers for Medicare and Medicaid Services, commonly known as CMS, did not apply the correct methodology when determining the insurer's star ratings under the Medicare Advantage program. Those ratings carry direct financial consequences for insurers, as they influence the reimbursement amounts that plans receive from the federal government.
The $115 million figure represents the amount Elevance contends it is owed as a result of what it characterises as flawed calculations by the agency.
Star Ratings and Insurer Payments
Medicare Advantage star ratings serve as a performance measurement system that links insurer compensation to assessed quality. Because the ratings feed directly into payment formulas, even incremental differences in how scores are calculated can translate into substantial sums for large insurers operating at scale.
The Elevance lawsuit underscores the financial stakes embedded in the rating methodology, and reflects the ongoing tension between private insurers participating in the Medicare Advantage market and the federal agency responsible for administering it.
Broader Context
Disputes over CMS methodology are not uncommon in the Medicare Advantage space, where the rules governing how performance is measured and how payments are determined have long been a source of contention between the agency and the insurers it oversees. Legal challenges represent one avenue through which insurers seek to contest agency determinations they regard as inaccurate or procedurally flawed.
The Elevance case, as reported by STAT News, adds to a pattern of friction between health insurers and federal regulators over the technical details of how star ratings are assigned and what financial consequences follow from those assignments.
The litigation remains ongoing, and the outcome could have implications for how CMS defends its rating calculations in future disputes.